ストックスクリーナーアプリを入手
2.515
2.24%
0.065
前日終値:
$2.45
開ける：
$2.45
24時間の取引高:
438.95K
Relative Volume:
0.14
時価総額：
$470.33M
収益：
$7.25M
当期純損益:
$-17.41M
株価収益率:
-9.5737
EPS:
-0.2627
ネットキャッシュフロー:
$-38.33M
1週間 パフォーマンス:
+4.81%
1か月 パフォーマンス:
-6.88%
6か月 パフォーマンス:
+53.68%
1年 パフォーマンス:
+759.64%
1日の値動き範囲:
$2.4301
$2.545
1週間の範囲:
$2.33
$2.545
52週間の値動き範囲:
$0.2701
$3.105
Ovid Therapeutics Inc Stock (OVID) Company Profile
名前
Ovid Therapeutics Inc
セクター
電話
212-776-4381
住所
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
Compare OVID vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
OVID
Ovid Therapeutics Inc
|
2.52 | 457.27M | 7.25M | -17.41M | -38.33M | -0.2627 |
VRTX
Vertex Pharmaceuticals Inc
|
441.18 | 110.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
629.36 | 66.53B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
828.44 | 50.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.77 | 39.45B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.97 | 32.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-11 | 開始されました | Roth Capital | Buy |
| 2025-11-17 | 開始されました | Leerink Partners | Outperform |
| 2025-10-09 | 開始されました | Oppenheimer | Outperform |
| 2025-08-08 | 再開されました | B. Riley Securities | Buy |
| 2024-06-18 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-04-30 | 開始されました | B. Riley Securities | Buy |
| 2024-04-29 | 開始されました | H.C. Wainwright | Buy |
| 2024-04-05 | 開始されました | Wedbush | Outperform |
| 2023-12-21 | 開始されました | BTIG Research | Buy |
| 2023-10-13 | 開始されました | Oppenheimer | Outperform |
| 2021-04-20 | ダウングレード | Cantor Fitzgerald | Buy → Neutral |
| 2021-03-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-12-02 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-12-02 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-04 | 開始されました | RBC Capital Mkts | Outperform |
| 2018-04-20 | 開始されました | Ladenburg Thalmann | Buy |
すべてを表示
Ovid Therapeutics Inc (OVID) 最新ニュース
OVID SEC FilingsOvid Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Point72 (OVID) discloses shared 1.3% position, including warrants - Stock Titan
Eventide (OVID) discloses 12.8M-share, 7.3% position in Ovid Therapeutics - Stock Titan
Ovid Therapeutics (OVID) Schedule 13G: Sirenia/manager report 9.9% stake - Stock Titan
Balyasny group holds 5.33% of Ovid (NASDAQ: OVID) across funds - Stock Titan
[SCHEDULE 13G/A] Ovid Therapeutics Inc. Amended Passive Investment Disclosure - Stock Titan
Jeremy Levin reports 4.5% stake in Ovid Therapeutics (NASDAQ: OVID) - Stock Titan
We're Hopeful That Ovid Therapeutics (NASDAQ:OVID) Will Use Its Cash Wisely - Yahoo Finance
Wedbush Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $7 - Moomoo
LifeSci Capital Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $5 - Moomoo
B.Riley reiterates Buy on Ovid Therapeutics stock, $5 target By Investing.com - Investing.com Australia
B.Riley reiterates Buy on Ovid Therapeutics stock, $5 target - Investing.com India
TD Cowen Maintains Ovid Therapeutics(OVID.US) With Buy Rating - Moomoo
Ovid Therapeutics 1Q Research and Development Expenses $11.2M >OVID - Moomoo
William Blair Maintains Ovid Therapeutics(OVID.US) With Buy Rating - Moomoo
Ovid Therapeutics earnings matched, revenue fell short of estimates By Investing.com - Investing.com Canada
OVID Sets Stage for Future Growth with Promising Pipeline Develo - GuruFocus
Ovid Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Ovid Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Ovid Therapeutics Reports Q1 2026 Results, Advances OV329 and OV4071 Clinical Programs, and Expands Pipeline for Pediatric Epilepsy and Psychosis 123 - Minichart
Ovid Therapeutics stock rises 4% on in-line results, pipeline progress By Investing.com - Investing.com South Africa
Ovid Therapeutics stock rises 4% on in-line results, pipeline progress - Investing.com UK
OVID: Advancing novel therapies for seizures and psychosis with strong safety and market potential - TradingView
Ovid Therapeutics : May 2026 Corporate Presentation - marketscreener.com
Ovid Therapeutics Q1 net loss widens as R&D spending rises - TradingView
Ovid Therapeutics Inc. 1Q 2026: Revenue $0M, Net loss $17M, EPS $(0.12) — 10-Q Summary - TradingView
Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results - The Manila Times
Ovid Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Ovid Therapeutics (NASDAQ: OVID) widens Q1 loss but boosts cash to $165.6M - Stock Titan
Ovid Therapeutics (NASDAQ: OVID) extends cash runway into 2029 - Stock Titan
TradingKey - TradingKey
Here is Why Ovid Therapeutics (OVID) is One of the Best Fast Growing Penny Stocks - Insider Monkey
Ovid Therapeutics (OVID) Eps Diluted (TTM) - Zacks Investment Research
5 Best Fast Growing Penny Stocks to Buy Right Now - Insider Monkey
Ovid Therapeutics Inc expected to post a loss of 12 cents a shareEarnings Preview - TradingView
MSN Money - MSN
Ovid Therapeutics (NASDAQ:OVID) Sees Large Decline in Short Interest - MarketBeat
OVID Earnings History & Surprises | EPS & Revenue Results | OVID THERAPEUTICS INC (NASDAQ:OVID) - ChartMill
Ovid Therapeutics (NASDAQ: OVID) outlines 2026 virtual meeting, pay and audit votes - Stock Titan
SEC Form DEFA14A filed by Ovid Therapeutics Inc. - Quantisnow
[ARS] Ovid Therapeutics Inc. SEC Filing - Stock Titan
Ovid Therapeutics (NASDAQ: OVID) registers 29.9M resale shares from private placement - Stock Titan
[EFFECT] Ovid Therapeutics Inc. SEC Filing - Stock Titan
OVID Ovid Therapeutics Inc. far exceeds Q4 2025 EPS expectations, shares rise nearly four percent.Profit Guidance - Cổng thông tin điện tử Tỉnh Sơn La
OVID (Ovid Therapeutics) delivers blowout Q4 2025 results, but stock dips slightly amid mild investor profit taking.Deceleration Risk - Xã Thanh Hà
29.86M-share resale registration by Ovid Therapeutics (NASDAQ: OVID) - Stock Titan
Ovid Therapeutics Inc (OVID) 財務データ
収益
当期純利益
現金流量
EPS
Ovid Therapeutics Inc (OVID) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| ALEXANDER MARGARET A. | President and CEO |
Feb 23 '26 |
Sale |
1.45 |
11,656 |
16,901 |
61,750 |
| Rona Jeffrey A | CBFO |
Feb 23 '26 |
Sale |
1.45 |
8,541 |
12,384 |
88,188 |
0.67%
1.91%
大文字化:
|
ボリューム (24 時間):